Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma

Song, Eyun; Jeon, Min Ji; Park, Suyeon; Kim, Mijin; Oh, Hye-Seon; Song, Dong Eun; Kim, Won Gu; Shong, Young Kee; Kim, Tae Yong

doi:10.1111/cen.13475

Cited by 43 publications

(48 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main characteristics of the 71 articles included in this meta-analysis are summarized in Table 1 [ 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 ]. A total of 44,034 participants with PTC were enrolled, of whom 11,132 (25.3%) had HT.…”

Section: Resultsmentioning

confidence: 99%

Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies

Moon

Chung

et al. 2018

Endocrinol Metab

View full text Add to dashboard Cite

BackgroundEpidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC.MethodsWe searched citation databases, including PubMed and Embase, for relevant studies from inception to September 2017. From these studies, we calculated the pooled odds ratios (ORs) of clinicopathologic features and the relative risk (RR) of PTC recurrence with 95% confidence intervals (CIs) using the Mantel-Haenszel method. Additionally, the Higgins I2 statistic was used to test for heterogeneity.ResultsThe meta-analysis included 71 published studies with 44,034 participants, among whom 11,132 had HT. We observed negative associations between PTC with comorbid HT and extrathyroidal extension (OR, 0.74; 95% CI, 0.68 to 0.81), lymph node metastasis (OR, 0.82; 95% CI, 0.72 to 0.94), distant metastasis (OR, 0.49; 95% CI, 0.32 to 0.76), and recurrence (RR, 0.50; 95% CI, 0.41 to 0.61).ConclusionIn this meta-analysis, PTC patients with HT appeared to exhibit more favorable clinicopathologic characteristics and a better prognosis than those without HT.

show abstract

Section: Resultsmentioning

confidence: 99%

Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies

Moon

Chung

et al. 2018

Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…In this regard, the association between thyroid carcinoma and chronic lymphocytic thyroiditis (CLT) has been carried out in numerous previous studies and is now generally accepted that CLT increases the risk of papillary thyroid carcinoma (PTC) . Notably however, when CLT coexists in patients with PTC, the clinical outcome is reported to be more favorable compared to cases without coexistent CLT, although controversies exist …”

Section: Introductionmentioning

confidence: 99%

The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma

Song

Jeon

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The link between chronic lymphocytic thyroiditis (CLT) and papillary thyroid carcinoma (PTC) is widely recognized. Considering the strong association between raised antithyroidperoxidase antibody (TPOAb) and CLT, we postulated that the preoperative TPOAb can predict the prognosis of PTC, particularly for recurrence. A total of 2,070 patients who underwent total thyroidectomy for classical type PTC with tumor size 1 cm and with available data on preoperative TPOAb and TgAb were enrolled to compare disease-free survival (DFS) according to the presence of preoperative TPOAb, TgAb, and coexistent CLT. Patients with positive preoperative TPOAb had a significantly better DFS compared to patients without positive preoperative TPOAb (hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.30-0.94, p = 0.028) while no difference in DFS was found according to preoperative TgAb status. Positive preoperative TPOAb was an independent prognostic factor for structural persistent/recurrent disease after adjustment for major preoperative risk factors such as age, sex, and tumor size (HR 0.52, 95% CI 0.28-0.99, p = 0.048). Although the coexistence of CLT lowered the risk for structural persistence/recurrence in univariate analysis (HR 0.52, 95% CI 0.31-0.86, p = 0.012), it was not an independent favorable prognostic factor by multivariate analysis (HR 0.65, 95% CI 0.38-1.10, p = 0.106). However, when coexistent CLT was combined with positive preoperative TPOAb, it indicated an independent protective role in structural persistent/recurrent disease (HR 0.39, 95% CI 0.16-0.98, p = 0.045). Our study clearly showed that presence of preoperative TPOAb can be a novel prognostic factor in predicting structural persistence/recurrence of PTC.

show abstract

“…Approximately 30% of DTC patients have evidence of autoimmune thyroiditis, and it is associated with favourable outcomes in DTCs. [5][6][7] However, tumour-associated macrophages (TAMs) are associated with de-differentiation and poor prognosis in thyroid cancer. [8][9][10] These suggested tumourrelated immune cells and microenvironments are important in the pathogenesis of thyroid cancer.…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of the lymphocyte‐to‐monocyte ratio for clinical outcomes of patients with progressive radioiodine‐refractory differentiated thyroid carcinoma treated by sorafenib

Ahn

Song

Kim

et al. 2019

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

Objectives:The lymphocyte-to-monocyte ratio (LMR) reflects the status of tumourinfiltrating immune cells and host immunity. The LMR has been reported as a prognostic marker in various cancers. The present study evaluated the role of the LMR as a prognostic marker in patients with progressive radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC). Design: Retrospective cohort study.Patients: Forty patients with progressive RAIR DTC who were treated by sorafenib with available baseline complete blood cell count data. Measurements:We assessed the response rate, progression-free survival (PFS) and overall survival (OS). Results:The patients were divided into low and high LMR groups based on their baseline LMRs (<4, n = 22, 55% and ≥4, n = 18, 45%, respectively). There were no significant differences in baseline characteristics between the groups. The OS curves differed significantly based on the LMR. The median OS of the low LMR group was 24.3 months and that of the high LMR group was not reached until the end of observation period (P = .015). The PFS curves and median PFS also differed significantly based on the LMR values (P = .019). In multivariate analysis, low LMR was an independent risk factor for all-cause mortality in patients with progressive RAIR DTC (hazard ratio, 2.64; 95% confidence interval: 1.04-6.72, P = .041). Conclusion:A low LMR was associated with poor response rate, PFS and OS in patients with progressive RAIR DTC treated with sorafenib. Thus, LMR could be a simple prognostic biomarker in patients with progressive RAIR DTC. K E Y W O R D Sdifferentiated thyroid carcinoma, immune system, lymphocyte, monocytes, sorafenib

show abstract

Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma

Cited by 43 publications

References 19 publications

Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies

Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies

The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma

Prognostic role of the lymphocyte‐to‐monocyte ratio for clinical outcomes of patients with progressive radioiodine‐refractory differentiated thyroid carcinoma treated by sorafenib

Contact Info

Product

Resources

About